Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | CIT | O14578 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.33 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17843977 | 0.97 | BRD4 (0.36) | BRD4CHRNB2CHRNA4PRKCIABL1 | |
| SCHEMBL10326422 | 0.81 | ABL1 (0.37) | BRD4PRKCIABL1RAD52RIN1 | |
| SCHEMBL10292445 | 0.81 | PIK3C3 (0.39) | BRD4PRKCIABL1RAD52RIN1 | |
| SCHEMBL1473221 | 0.81 | BRD4 (0.40) | BRD4ABL1RAD52RIN1CFB | |
| Hydrochloric Acid SCHEMBL3558795 | 0.79 | BRD4 (0.39) | BRD4ABL1RAD52RIN1CFB | |
| SCHEMBL3570127 | 0.79 | BRD4 (0.36) | BRD4ABL1RAD52RIN1JAK1 | |
| SCHEMBL1473430 | 0.79 | DYRK1A (0.41) | BRD4PRKCIDYRK1ACFB | |
| SCHEMBL1473045 | 0.77 | CFB (0.40) | BRD4CFBPRKCQPRKCD | |
| SCHEMBL2211568 | 0.76 | PRKCI (0.42) | PRKCIDYRK1ACFB | |
| SCHEMBL31275318 | 0.76 | PRKCI (0.42) | PRKCIDYRK1ACFB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| CN-114401731-A | Compositions and methods for treating human immunodeficiency virus | 奇达拉治疗公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3982993-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020252393-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-9908882-B2 | Process for preparing halogenated azaindole compounds using boroxine | ViiV Healthcare UK (No.4) Limited (GB) | 2018-03-06 | — | — | US | disclosed |
| US-9908882-B2 | Process for preparing halogenated azaindole compounds using boroxine | ViiV Healthcare UK (No.4) Limited (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20170362262-A1 | A PROCESS FOR PREPARING HALOGENATED AZAINDOLE COMPOUNDS USING PYBROP | BRISTOL-MYERS SQUIBB COMPANY | 2017-12-21 | — | — | US | disclosed |
| US-20170362262-A1 | A PROCESS FOR PREPARING HALOGENATED AZAINDOLE COMPOUNDS USING PYBROP | BRISTOL-MYERS SQUIBB COMPANY | 2017-12-21 | — | — | US | disclosed |
| US-20170298064-A1 | PROCESS FOR PREPARING HALOGENATED AZAINDOLE COMPOUNDS USING BOROXINE | ViiV Healthcare UK (No.4) Limited (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170298064-A1 | PROCESS FOR PREPARING HALOGENATED AZAINDOLE COMPOUNDS USING BOROXINE | ViiV Healthcare UK (No.4) Limited (GB) | 2017-10-19 | — | — | US | disclosed |
| US-7348337-B2 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2007127731-A1 | 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127731-A1 | 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249624-A1 | 4-Squarylpiperazine Derivatives as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20070249624-A1 | 4-Squarylpiperazine Derivatives as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20070249624-A1 | 4-Squarylpiperazine Derivatives as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| EP-1513832-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | Bristol-Myers Squibb Company (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-09-23 | — | — | US | disclosed |
| WO-2004043337-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040063744-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362262-A1 | A PROCESS FOR PREPARING HALOGENATED AZAINDOLE COMPOUNDS USING PYBROP | PAXBP1, AZI2, PML | BRD4 110/4885CHRNB2 4170/4885CHRNA4 4650/4885 |
| US-20040063744-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | IDO1, IDO2, INMT | BRD4 25/4885CHRNB2 4499/4885CHRNA4 2786/4885 |
| US-20170298064-A1 | PROCESS FOR PREPARING HALOGENATED AZAINDOLE COMPOUNDS USING BOROXINE | BRI3BP, AZI2, BRIX1 | BRD4 40/4885CHRNB2 1560/4885CHRNA4 1404/4885 |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | IDO1, IDO2, INMT | BRD4 25/4885CHRNB2 4499/4885CHRNA4 2786/4885 |
| US-20070249624-A1 | 4-Squarylpiperazine Derivatives as Antiviral Agents | MAVS, MTAP, SAMHD1 | BRD4 1165/4885CHRNB2 4736/4885CHRNA4 4335/4885 |
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | FCGR3B, FCGR1A, FCGR2A | BRD4 3294/4885CHRNB2 4559/4885CHRNA4 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.